Published in Antimicrob Agents Chemother on May 01, 1997
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Detection of Cryptococcus neoformans DNA in tissue samples by nested and real-time PCR assays. Clin Diagn Lab Immunol (2002) 1.27
Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.23
In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother (2004) 1.21
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother (2006) 1.13
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother (2003) 1.01
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother (2004) 0.88
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 0.88
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother (2004) 0.83
In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother (2005) 0.81
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis. Antimicrob Agents Chemother (2016) 0.75
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med (1990) 3.26
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J Infect Dis (1996) 1.01
Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole. Lancet (1995) 0.89
Multidermatomal herpes zoster in an AIDS patient. Clin Infect Dis (1994) 0.85
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
Recursive partitioning for tumor classification with gene expression microarray data. Proc Natl Acad Sci U S A (2001) 2.66
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired. Nat Genet (1998) 2.26
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis (1984) 2.03
Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J (1987) 2.00
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis (1973) 1.91
Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother (1997) 1.87
Mosaic autosomal trisomy in cultures from spontaneous abortions. Am J Hum Genet (1978) 1.80
Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis (1982) 1.77
Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother (1981) 1.77
Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol (1986) 1.69
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother (1998) 1.69
Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1996) 1.68
Penetration of brain abscess by systemically administered antibiotics. J Neurosurg (1973) 1.68
Disseminated mycobacteriosis due to Mycobacterium abcessus in two recipients of renal homografts. Am Rev Respir Dis (1974) 1.66
Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother (1989) 1.61
Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol (2008) 1.60
Passive immunization in murine cryptococcosis. Sabouraudia (1981) 1.59
Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis (1981) 1.58
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother (1998) 1.55
Structural basis of the polymorphism of human complement components C4A and C4B: gene size, reactivity and antigenicity. EMBO J (1986) 1.54
Tree-based linkage and association analyses of asthma. Genet Epidemiol (2001) 1.52
The dichotomous size variation of human complement C4 genes is mediated by a novel family of endogenous retroviruses, which also establishes species-specific genomic patterns among Old World primates. Immunogenetics (1994) 1.52
Host defense in cryptococcosis. II. Cryptococcosis in the nude mouse. Cell Immunol (1978) 1.52
High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med (1984) 1.51
Definitive RFLPs to distinguish between the human complement C4A/C4B isotypes and the major Rodgers/Chido determinants: application to the study of C4 null alleles. Immunogenetics (1987) 1.49
Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother (1986) 1.49
Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis (1990) 1.46
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother (1997) 1.46
Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole. J Clin Microbiol (1999) 1.46
Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med (1988) 1.45
Detection of Paracoccidioides brasiliensis in tissue samples by a nested PCR assay. J Clin Microbiol (2000) 1.44
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1996) 1.41
Variability of sequential studies of lymphocyte blastogenesis in normal adults. Clin Exp Immunol (1976) 1.40
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (2001) 1.39
Host defense in cryptococcosis. I. An in vivo model for evaluating immune response. Int Arch Allergy Appl Immunol (1978) 1.38
Human helicase gene SKI2W in the HLA class III region exhibits striking structural similarities to the yeast antiviral gene SKI2 and to the human gene KIAA0052: emergence of a new gene family. Nucleic Acids Res (1995) 1.37
Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother (1992) 1.37
Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J Infect Dis (1979) 1.36
Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs (1983) 1.35
Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother (1987) 1.34
High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med (1983) 1.33
G alpha 13 stimulates Na+-H+ exchange through distinct Cdc42-dependent and RhoA-dependent pathways. J Biol Chem (1996) 1.32
Histoplasma capsulatum infection in nude mice. Infect Immun (1978) 1.31
Complement component C4 gene intron 9 as a phylogenetic marker for primates: long terminal repeats of the endogenous retrovirus ERV-K(C4) are a molecular clock of evolution. Immunogenetics (1995) 1.28
Polymorphism of human complement component C4. Immunogenetics (1985) 1.28
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agents Chemother (1996) 1.28
Immunologic and clinical improvement of progressive coccidioidomycosis following administration of transfer factor. Cell Immunol (1973) 1.27
Fungal infections in AIDS patients. J Med Vet Mycol (1992) 1.27
Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother (1998) 1.27
Diagnosis and monitoring of murine histoplasmosis by a nested PCR assay. J Clin Microbiol (2001) 1.27
Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis (1986) 1.23
Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol (2001) 1.23
Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. Am J Med (1988) 1.22
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Comparison of PCR and culture to the indirect fluorescent-antibody test for diagnosis of Potomac horse fever. J Clin Microbiol (1997) 1.20
Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother (1998) 1.19
Itraconazole treatment of murine aspergillosis. Sabouraudia (1985) 1.16
Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother (1998) 1.16
Sulfur granules. Second thoughts. Arch Intern Med (1969) 1.15
SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother (2000) 1.13
Disseminated Mycobacterium simiae infection in patients with AIDS. J Infect (2000) 1.13
Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response? Antimicrob Agents Chemother (1995) 1.12
Treatment of experimental murine aspergillosis with BAY n7133. J Infect Dis (1983) 1.12
Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother (1997) 1.12
High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother (1991) 1.12
Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med (1993) 1.11
Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination. Antimicrob Agents Chemother (1991) 1.10
R 51211 (itraconazole) therapy of murine cryptococcosis. Sabouraudia (1984) 1.10
Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. J Antimicrob Chemother (1995) 1.10
Experimental chemotherapy of histoplasmosis in nude mice. Am Rev Respir Dis (1979) 1.08
Renal tubular acidosis complicated with hypokalemic periodic paralysis. Pediatr Neurol (1995) 1.07
Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol (2002) 1.07
Molecular basis of complete complement C4 deficiency in two North-African families with systemic lupus erythematosus. Genes Immun (2009) 1.07
Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother (2000) 1.07
Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis (1990) 1.06
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother (1998) 1.05
Ketoconazole: a major innovation for treatment of fungal disease. Ann Intern Med (1980) 1.04
The human DEVH-box protein Ski2w from the HLA is localized in nucleoli and ribosomes. Nucleic Acids Res (1998) 1.04
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Ketoconazole therapy of murine cryptococcal meningitis. Am Rev Respir Dis (1982) 1.03
Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother (2001) 1.02